BTAI BioXcel Therapeutics

BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast

BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast

NEW HAVEN, Conn., May 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Tuesday, May 12, 2020 at 8:30 AM Eastern Time to discuss its first quarter 2020 operating and financial results.

Conference Call & Webcast Details

Date/Time: Tuesday, May 12, 2020, 8:30 AM Eastern Time

Domestic: 877-407-2985

International: 201-378-4915

The webcast will be accessible* under "Events" on the News & Media page of the Company's website at .

Replay

Domestic: 877-660-6853

International: 201-612-7415

Conference ID: 13703343

*Replay available through May 26, 2020

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit .

Contact Information:

BioXcel Therapeutics, Inc.

Investor Relations:

John Graziano

1.646.378.2942

Media:

Julia Deutsch

1.646.378.2967

EN
05/05/2020

Underlying

BTAIBioXcel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioXcel Therapeutics

 PRESS RELEASE
Free
BTAI BioXcel Therape...

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable w...

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disor...

December 3, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and ...

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the SERENITY At-Home trial NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported financial results for the third quarter of...

November 12, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Announces Positive Results from Correlation Study...

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026 NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive results from the correlation study related to exploratory efficacy outcomes from the SERENITY At-Home trial. The results, along w...

October 14, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Cele...

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough pr...

October 13, 2025 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Li...

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “...

September 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch